BioSpace News Archive

Affinity Bio Partners Affinity BioCeuticals and HCXperience announced that they are technology partners.

EyeGate Pharma today announced that it has been granted U.S. Patent No. 9,820,935, by the USPTO.

Under terms of the 18-month agreement, Chembio will receive up to $2.9M in funding from Astra.

Xbrane Biopharma has signed a distribution agreement with BL&H for sales and marketing of Spherotide in South Korea. Xbrane will receive mid-single digit SEK million license fee for the exclusive rights to Spherotide in South Korea and Xbrane and BL&H will share the profits from sales. Timing of launch is expected to earliest 2019.

BioMarin announced today that it has dosed the first patient in the global GENEr8-1 Phase 3 study with the 6e13 vg/kg dose for valoctocogene roxaparvovec.

Under the terms of the agreement, X-Chem will utilize its DNA-encoded library (DEXTM) screening and informatics platform to search for novel drug leads for several Otsuka discovery targets.

Dr. Michael Goldberg, Chief Executive Officer of Navidea, will be giving a presentation and meeting with investors.

Crucial Data Solutions offers fully-featured app for EDC in clinical trials, an ideal alternative to Apple’s ResearchKit framework.

Following the transaction, CPM will be a wholly-owned subsidiary of Fuse.

RGX-121 has received orphan drug designation as well as rare pediatric disease designation from the FDA.